Literature DB >> 31773415

Chemokines and their receptors as biomarkers in esophageal cancer.

Masakazu Goto1,2, Mingyao Liu3,4.   

Abstract

Esophageal cancer (EC) is one of the most lethal malignancies of the digestive tract and remains to be improved poor prognosis. Two histological subtypes, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), are major characteristics of EC. Deep understanding about both subtypes is essential to overcome EC. Here, we focus on chemokines and their receptors as biomarkers and their current applications for the prognosis in EC. We reviewed relevant articles identified using PubMed database for the chemokines and their receptors in EC analyzed by immunohistochemistry. The primary objective is to summarize evidences for them as prognostic biomarkers in EC. A total of twenty-one articles were reviewed after exclusion. Most studies have been done in ESCC, and less in EAC. CXCL12 and its receptor CXCR4 have been shown in both subtypes as biomarkers. CXCR7, CXCL8 and its receptor CXCR2, and CCL21 and its receptor CCR7 have been examined in ESCC. Although it was a small number of reports, CXCL10, CCL4, and CCL5 have been indicated to have anti-tumor effects in ESCC. Chemokines and their receptors have the potential to be the biomarkers in EC. Comparative studies between ESCC and EAC will reveal the similarity and difference in these two subtypes of EC. These studies may indicate whether these molecules play important roles in both subtypes or are unique to one or another.

Entities:  

Keywords:  Biomarker; Chemokine; Esophageal adenocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31773415     DOI: 10.1007/s10388-019-00706-8

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  50 in total

1.  Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer.

Authors:  Kenji Koishi; Reigetsu Yoshikawa; Tohru Tsujimura; Tomoko Hashimoto-Tamaoki; Syoudou Kojima; Hidenori Yanagi; Takehira Yamamura; Yoshinori Fujiwara
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

2.  Silencing of CXCR2 and CXCR7 protects against esophageal cancer.

Authors:  Kai Wu; Lingling Cui; Yang Yang; Jia Zhao; Dengyan Zhu; Donglei Liu; Chunyang Zhang; Yu Qi; Xiangnan Li; Weihao Li; Song Zhao
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

3.  High expression of CXCR-2 correlates with lymph node metastasis and predicts unfavorable prognosis in resected esophageal carcinoma.

Authors:  Ping Sui; Pingping Hu; Tiehong Zhang; Xiangwei Zhang; Qi Liu; Jiajun Du
Journal:  Med Oncol       Date:  2013-12-17       Impact factor: 3.064

Review 4.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.

Authors:  Daniel J Brat; Anita C Bellail; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

5.  Cancer-associated fibroblast-derived CXCL12 causes tumor progression in adenocarcinoma of the esophagogastric junction.

Authors:  Hidetaka Sugihara; Takatsugu Ishimoto; Tadahito Yasuda; Daisuke Izumi; Kojiro Eto; Hiroshi Sawayama; Keisuke Miyake; Junji Kurashige; Yu Imamura; Yukiharu Hiyoshi; Masaaki Iwatsuki; Shiro Iwagami; Yoshifumi Baba; Yasuo Sakamoto; Yuji Miyamoto; Naoya Yoshida; Masayuki Watanabe; Hiroshi Takamori; Hideo Baba
Journal:  Med Oncol       Date:  2015-04-24       Impact factor: 3.064

6.  Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma.

Authors:  Yongzeng Ding; Yutaka Shimada; Masato Maeda; Atsushi Kawabe; Junichi Kaganoi; Izumi Komoto; Yosuke Hashimoto; Masayuki Miyake; Hiroki Hashida; Masayuki Imamura
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

Review 7.  Epidemiology of esophageal cancer.

Authors:  Yuwei Zhang
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

8.  CXCR7 expression in esophageal cancer.

Authors:  Michael Tachezy; Hilke Zander; Florian Gebauer; Katharina von Loga; Klaus Pantel; Jakob R Izbicki; Maximilian Bockhorn
Journal:  J Transl Med       Date:  2013-09-30       Impact factor: 5.531

9.  Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma.

Authors:  Jinyan Liu; Feng Li; Yu Ping; Liping Wang; Xinfeng Chen; Dan Wang; Ling Cao; Song Zhao; Bing Li; Pawel Kalinski; Stephen H Thorne; Bin Zhang; Yi Zhang
Journal:  Oncotarget       Date:  2015-09-22

10.  CCL21-CCR7 promotes the lymph node metastasis of esophageal squamous cell carcinoma by up-regulating MUC1.

Authors:  Mo Shi; Dong Chen; Dong Yang; Xiang-Yan Liu
Journal:  J Exp Clin Cancer Res       Date:  2015-12-15
View more
  13 in total

Review 1.  Circulating Tumor Cells: Does Ion Transport Contribute to Intravascular Survival, Adhesion, Extravasation, and Metastatic Organotropism?

Authors:  Christian Stock
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

Review 2.  The Role of CCL21/CCR7 Chemokine Axis in Breast Cancer Progression.

Authors:  Balsam Rizeq; Mohammed Imad Malki
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

3.  Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients.

Authors:  Zide Zhang; Chong Liu; Tuo Liang; Chaojie Yu; Zhaojie Qin; Xin Zhou; Jiang Xue; Haopeng Zeng; Zhaojun Lu; Guoyong Xu; Zequn Wang; Jiarui Chen; Jie Jiang; Xinli Zhan
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.889

Review 4.  Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy.

Authors:  Ajaz A Bhat; Sabah Nisar; Selma Maacha; Tatiana Correa Carneiro-Lobo; Sabah Akhtar; Kodappully Sivaraman Siveen; Nissar A Wani; Arshi Rizwan; Puneet Bagga; Mayank Singh; Ravinder Reddy; Shahab Uddin; Jean-Charles Grivel; Gyan Chand; Michael P Frenneaux; Mushtaq A Siddiqi; Davide Bedognetti; Wael El-Rifai; Muzafar A Macha; Mohammad Haris
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

5.  HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.

Authors:  Jindong Li; Chengyan Jin; Lihua Sun; Bin Wang; Peiyan Hua; Yan Zhang
Journal:  Clin Epigenetics       Date:  2021-04-29       Impact factor: 6.551

6.  Identification of Molecular Biomarkers and Key Pathways for Esophageal Carcinoma (EsC): A Bioinformatics Approach.

Authors:  Md Rakibul Islam; Mohammad Khursheed Alam; Bikash Kumar Paul; Deepika Koundal; Atef Zaguia; Kawsar Ahmed
Journal:  Biomed Res Int       Date:  2022-01-12       Impact factor: 3.411

7.  Prognostic Values and Underlying Regulatory Network of Cohesin Subunits in Esophageal Carcinoma.

Authors:  Wenqiang Gan; Weiqi Wang; Tiegang Li; Rixin Zhang; Yufang Hou; Silin Lv; Zifan Zeng; Zheng Yan; Min Yang
Journal:  J Cancer       Date:  2022-03-06       Impact factor: 4.207

Review 8.  CXCL12 Signaling in the Tumor Microenvironment.

Authors:  Luigi Portella; Anna Maria Bello; Stefania Scala
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Prognostic Significance of the Combination of Fibrinogen and Tumor Marker Index in Esophageal Squamous Cell Carcinoma Patients.

Authors:  Yufeng Qiao; Mingquan Ma; Hongdian Zhang; Zhentao Yu; Peng Tang
Journal:  Onco Targets Ther       Date:  2021-02-17       Impact factor: 4.147

10.  The effect of CCL5 on the immune cells infiltration and the prognosis of patients with kidney renal clear cell carcinoma.

Authors:  Shuheng Bai; YinYing Wu; Yanli Yan; Haojing Kang; Jiangzhou Zhang; Wen Ma; Ying Gao; Beina Hui; Rong Li; Xiaozhi Zhang; Juan Ren
Journal:  Int J Med Sci       Date:  2020-10-18       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.